“…Ketamine is a non-competitive N-Methyl-D-aspartate receptor (NMDAR) antagonist investigated for its psychotomimetic properties ( 1 , 2 ) and has, among other NMDAR antagonists, been used to model positive, negative and cognitive symptoms of schizophrenia (SZ) ( 3 , 4 ). More recently, ketamine has gained attention for its robust, long-lasting, rapid-acting antidepressant (RAAD) effects ( 5 , 6 ). The mechanism of therapeutic effect remains un-elucidated and understanding RAAD pathways is complicated by ketamine's affinities to receptors in opioid, norepinephric, dopaminergic and serotonergic systems ( 1 , 7 , 8 ).…”